Trust Investment Advisors Buys 76 Shares of Danaher Co. (NYSE:DHR)

Trust Investment Advisors raised its stake in Danaher Co. (NYSE:DHR) by 2.7% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,881 shares of the conglomerate’s stock after purchasing an additional 76 shares during the quarter. Trust Investment Advisors’ holdings in Danaher were worth $720,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in DHR. Vanguard Group Inc. grew its stake in shares of Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after buying an additional 4,163,657 shares in the last quarter. Wellington Management Group LLP raised its position in Danaher by 12.0% during the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after acquiring an additional 2,998,161 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after acquiring an additional 1,619,586 shares during the last quarter. Capital International Investors grew its position in shares of Danaher by 9.1% in the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after acquiring an additional 1,334,781 shares during the period. Finally, Edgewood Management LLC increased its stake in shares of Danaher by 7.7% during the 4th quarter. Edgewood Management LLC now owns 6,381,293 shares of the conglomerate’s stock worth $1,476,248,000 after purchasing an additional 454,950 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of Danaher stock opened at $276.43 on Friday. The company has a 50-day simple moving average of $267.10 and a two-hundred day simple moving average of $257.03. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The stock has a market capitalization of $204.75 billion, a price-to-earnings ratio of 46.85, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.05 earnings per share. Analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,659 shares of company stock worth $11,042,433. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. TD Cowen lifted their target price on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group boosted their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Stifel Nicolaus raised their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.